Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Single-cell and spatial multi-omics redefine immunotherapy resistance biomarkers

A cancer review links single-cell and spatial multi-omics to immune microenvironment heterogeneity, resistance biology, and better biomarker design.

A JCO commentary examines why treatment sequence in international breast cancer trials can reshape interpretation, endpoints, and clinical…

A JCO commentary examines postapproval barriers that can delay access to new lung cancer therapies after regulatory approval.

JCO commentary revisits 65 years of corticosteroid use in glioblastoma, questioning routine reliance on dexamethasone and its neurological…

A JCO commentary calls for pragmatic breast cancer radiotherapy de-escalation studies and points to trial design barriers in…

NICE issued technology appraisal guidance for nirogacestat in adult desmoid tumours, with NHS access via a simple discount…

A JCO commentary examines how precision oncology is reshaping care for cancer of unknown primary and why molecularly…

A JCO correspondence replies to criticism of TRANSFORM ctDNA interpretation, focusing on assessment timing, event definitions, and subset…

JCO correspondence warns against using endoscopic response alone to choose nonoperative management in RESET-C, stressing caution before changing…

JCO correspondence reply on radiographic progression and PSA rise in advanced prostate cancer treated with enzalutamide, with author…

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds